[go: up one dir, main page]

MXPA06000332A - Nueva composicion farmaceutica solida que comprende amisulprida. - Google Patents

Nueva composicion farmaceutica solida que comprende amisulprida.

Info

Publication number
MXPA06000332A
MXPA06000332A MXPA06000332A MXPA06000332A MXPA06000332A MX PA06000332 A MXPA06000332 A MX PA06000332A MX PA06000332 A MXPA06000332 A MX PA06000332A MX PA06000332 A MXPA06000332 A MX PA06000332A MX PA06000332 A MXPA06000332 A MX PA06000332A
Authority
MX
Mexico
Prior art keywords
amisulpride
pharmaceutical composition
solid pharmaceutical
novel solid
composition
Prior art date
Application number
MXPA06000332A
Other languages
English (en)
Inventor
Agnes Ribardiere
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of MXPA06000332A publication Critical patent/MXPA06000332A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005Wall or coating material
    • A61K9/5015Organic compounds, e.g. fats, sugars
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005Wall or coating material
    • A61K9/5021Organic macromolecular compounds
    • A61K9/5026Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005Wall or coating material
    • A61K9/5021Organic macromolecular compounds
    • A61K9/5036Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Zoology (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invencion se refiere a una nueva composicion farmaceutica solida para administracion por via oral del principio activo amisulprida, caracterizada porque comprende al menos una particula de amisulprida recubierta y al menos un excipiente farmaceuticamente aceptable adaptado a una administracion orodispersable de la composicion. Esta nueva composicion puede en particular presentarse en forma de un comprimido orodispersable de amisulprida.
MXPA06000332A 2003-07-09 2004-07-08 Nueva composicion farmaceutica solida que comprende amisulprida. MXPA06000332A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0308409A FR2857263B1 (fr) 2003-07-09 2003-07-09 Nouvelle composition pharmaceutique solide comprenant de l'amisulpride
PCT/FR2004/001792 WO2005004860A2 (fr) 2003-07-09 2004-07-08 Nouvelle composition pharmaceutique solide comprenant de l'amisulpride

Publications (1)

Publication Number Publication Date
MXPA06000332A true MXPA06000332A (es) 2006-03-30

Family

ID=33522905

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA06000332A MXPA06000332A (es) 2003-07-09 2004-07-08 Nueva composicion farmaceutica solida que comprende amisulprida.

Country Status (14)

Country Link
US (1) US20060153925A1 (es)
EP (1) EP1646379B1 (es)
JP (1) JP2007516188A (es)
KR (1) KR20060032628A (es)
CN (1) CN1842331A (es)
AU (1) AU2004255504A1 (es)
BR (1) BRPI0412364A (es)
CA (1) CA2529461A1 (es)
FR (1) FR2857263B1 (es)
IL (1) IL172814A0 (es)
MX (1) MXPA06000332A (es)
NO (1) NO20060445L (es)
WO (1) WO2005004860A2 (es)
ZA (1) ZA200600159B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2894475B1 (fr) * 2005-12-14 2008-05-16 Servier Lab Composition pharmaceutique orodispersible pour administra- -tion oromucosale ou sublinguale d'agomelatine
EP1935405A1 (en) * 2006-12-22 2008-06-25 LEK Pharmaceuticals D.D. Orally disintegrating tablets
WO2010023690A2 (en) * 2008-08-28 2010-03-04 Torrent Pharmaceuticals Ltd. Prolonged release formulation of amisulpride
FR2959130A1 (fr) * 2010-04-21 2011-10-28 Sanofi Aventis Procede de preparation de compositions pharmaceutiques destinees a l'administration par voie orale comprenant un ou plusieurs principes actifs et les compositions les comprenant.
AU2010363655B2 (en) * 2010-11-08 2015-01-22 Colgate-Palmolive Company Oral compositions containing microaggregates
FR3008900B1 (fr) * 2013-07-25 2018-03-30 Centre Nat Rech Scient Nanoparticules lipidiques multicompartimentees
CN107126422B (zh) * 2017-03-02 2020-07-07 河北龙海药业有限公司 一种氨磺必利片剂及其制备方法
CN118955352A (zh) 2017-12-05 2024-11-15 赛诺维信制药公司 晶体形式及其制备方法
CN112118838A (zh) 2017-12-05 2020-12-22 赛诺维信制药公司 非外消旋混合物及其用途
JP7233852B2 (ja) * 2018-04-17 2023-03-07 キョーリンリメディオ株式会社 変色が抑制された固形製剤
CN110613690A (zh) * 2018-06-19 2019-12-27 北京万全德众医药生物技术有限公司 一种氨磺必利口崩片及其制备方法
CN109010300A (zh) * 2018-10-24 2018-12-18 湖南洞庭药业股份有限公司 一种氨磺必利片及其制备方法
WO2020247627A1 (en) 2019-06-04 2020-12-10 Sunovion Pharmaceuticals Inc. Modified release formulations and uses thereof
CN112089698A (zh) * 2020-10-23 2020-12-18 江苏阿尔法药业有限公司 氨磺必利片及其制备方法
CN115487161B (zh) * 2022-11-18 2023-03-03 山东则正医药技术有限公司 一种氨磺必利片的制备方法
TW202529747A (zh) * 2023-10-06 2025-08-01 美商Lb製藥股份有限公司 抗精神病藥劑之用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2415099A1 (fr) * 1978-01-20 1979-08-17 Ile De France Nouveaux derives de 4-amino-5-alkylsulfonyl ortho-anisamides, leurs procedes de preparation et leur application comme psychotropes
ATE260646T1 (de) * 1996-04-16 2004-03-15 Novartis Consumer Health Sa Schnell zerfallende orale dosierungsform
FR2753639B1 (fr) * 1996-09-25 1998-12-11 Procede de preparation de microcapsules de matieres actives enrobees par un polymere et nouvelles microcapsules notamment obtenues selon le procede
ATE216220T1 (de) * 1997-12-05 2002-05-15 Alza Corp Osmotische darreichungsform mit zwei mantelschichten
FR2790388B1 (fr) * 1999-03-04 2001-04-13 Synthelabo Compositions pharmaceutiques comprenant un benzamide et au moins un promoteur d'absorption
US6723348B2 (en) * 2001-11-16 2004-04-20 Ethypharm Orodispersible tablets containing fexofenadine
FR2834889B1 (fr) * 2002-01-18 2004-04-02 Roquette Freres Forme pharmaceutique solide orodispersible

Also Published As

Publication number Publication date
NO20060445L (no) 2006-01-27
FR2857263B1 (fr) 2005-09-09
KR20060032628A (ko) 2006-04-17
AU2004255504A1 (en) 2005-01-20
CA2529461A1 (fr) 2005-01-20
WO2005004860A2 (fr) 2005-01-20
ZA200600159B (en) 2007-03-28
CN1842331A (zh) 2006-10-04
WO2005004860A3 (fr) 2005-04-14
FR2857263A1 (fr) 2005-01-14
IL172814A0 (en) 2006-06-11
EP1646379B1 (fr) 2013-09-18
BRPI0412364A (pt) 2006-09-05
US20060153925A1 (en) 2006-07-13
EP1646379A2 (fr) 2006-04-19
JP2007516188A (ja) 2007-06-21

Similar Documents

Publication Publication Date Title
TW200505498A (en) Sugar-free oral transmucosal solid dosage forms and uses thereof
MXPA06000332A (es) Nueva composicion farmaceutica solida que comprende amisulprida.
AU2003274681A1 (en) Dosage form comprising high dose high soluble active ingredient as modified release and low dose active ingredient as immediate release
WO2003047519A3 (en) 'compressed annular tablet with molded triturate tablet for oral and intraoral'
DE60121570D1 (de) Oral anzuwendende schnell zerfallende feste darreichungsformen
WO2001041770A3 (en) Nanoparticulate eplerenone compositions
HUP0302319A3 (en) Pharmaceutical composition for oral administration of active ingredient
BG66093B1 (bg) Състави с контролирано освобождаване, съдържащи нимесулид
MX2007015480A (es) Formulaciones de dosificacion solida de medicamentos narcoticos que tienen adsorcion bucal mejorada.
WO2008142572A3 (en) Controlled release tablet formulation containing magnesium aluminometasilicate
MY127350A (en) Flash-melt oral dose formulations
CY1107295T1 (el) Σταθεροποιηση στερεων φορμουλων φαρμακων του θυρεοειδους
DE69923336D1 (de) Oral anzuwendende buprenorphinhaltige arzneimittel
AP2003002763A0 (en) Controlled release formulations for oral administration
MXPA03002807A (es) Estabilizacion de formulaciones solidas de farmacos.
DE60102590T2 (de) Darreichungsformen zur behandlung von oralen mykosen
PL377683A1 (pl) System terapeutyczny zawierający amoksycylinę i kwas klawulanowy
WO2003061557A3 (en) Levothyroxine pharmaceutical compositions, methods of making and methods of administration
PL378106A1 (pl) Sposób wytwarzania zawierającej fibrat kompozycji farmaceutycznej w postaci tabletek oraz tabletki otrzymane tym sposobem
NZ594669A (en) Oral composition of Vorinostat
ATE401075T1 (de) Cytisinehaltiges arzneimittel
WO2005115346A3 (en) Pharmaceutical composition containing risperidone
WO2004014318A3 (en) Levothyroxine compositions and methods
PL1499278T3 (pl) Farmaceutyczna postać użytkowa o natychmiastowym uwalnianiu zawierająca polimorficzny tibolon
IL164763A0 (en) Byperforin derivatives, the use thereof and formulations containing them